Malyukova, Alena
Lahnalampi, Mari
Falqués-Costa, Ton
Pölönen, Petri
Sipola, Mikko
Mehtonen, Juha
Teppo, Susanna
Akopyan, Karen
Viiliainen, Johanna
Lohi, Olli
Hagström-Andersson, Anna K.
Heinäniemi, Merja http://orcid.org/0000-0001-6190-3439
Sangfelt, Olle
Funding for this research was provided by:
Barncancerfonden
Swedish Cancer Foundation
Vetenskapsrådet ((2020-01243), 201333, 201173-Pj, 222248-Pj PR2019-0060, PR2022-0021, 2022-01717)
Radiumhemmets Forskningsfonder
Academy of Finland (321553, 310106)
H2020 European Research Council (824110, ERAPERMED2018-209)
Lasten Syöpäsäätiö Väreen
Emil Aaltosen Säätiö
Syöpäsäätiö
Jane ja Aatos Erkon Säätiö
Sigrid Juséliuksen Säätiö
AstraZeneca (18122013)
Article History
Received: 15 May 2023
Accepted: 26 April 2024
First Online: 31 May 2024
Declarations
:
: Collection of blood and bone marrow samples during induction chemotherapy was approved by the Regional Ethics Committee in Pirkanmaa, Tampere, Finland (#R13109), and conducted according to the guidelines of the Declaration of Helsinki. A written informed consent was received by the patient and/or guardians. PDX studies had prior approval from the Human Research Ethics Committees of the University of New South Wales. Mice were bred and maintained in accordance with Lund University’s ethical regulations and approved by the local ethics committee of Lund, Sweden.
: Not applicable.
: The authors declare that they have no competing interests.